Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year EssilorLuxottica SA grew revenues 3.68% from 24.49bn to 25.40bn while net income improved 6.32% from 2.15bn to 2.29bn.
Gross margin62.34%
Net profit margin9.38%
Operating margin12.72%
Return on assets3.98%
Return on equity5.98%
Return on investment4.88%
More ▼

Cash flow in EURView more

In 2023, EssilorLuxottica SA increased its cash reserves by 30.51%, or 598.00m. The company earned 4.86bn from its operations for a Cash Flow Margin of 19.14%. In addition the company used 1.72bn on investing activities and also paid 2.43bn in financing cash flows.
Cash flow per share11.89
Price/Cash flow per share19.23
Book value per share85.66
Tangible book value per share-5.09
More ▼

Balance sheet in EURView more

EssilorLuxottica SA has a Debt to Total Capital ratio of 23.13%, a lower figure than the previous year's 23.59%.
Current ratio0.8847
Quick ratio0.6224
Total debt/total equity0.3055
Total debt/total capital0.2313
More ▼

Growth rates in EUR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 22.29% and 5.16%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Medical Equipment & Supplies industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)1.49%
Div growth rate (5 year)14.13%
Payout ratio (TTM)77.89%
EPS growth(5 years)4.52
EPS (TTM) vs
TTM 1 year ago
17.11
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.